Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
U-Neuron BiomedicalROCO:6973 -0.55%36 Debt-to-Equity is 0.04 as of Jun. 2026, which is 100% above its 10-year median of 0.02. GuruFocus rates ROCO:6973 with a GF Score™ of 36/100 and a GF Value™ of NT$70.46 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 962 Biotechnology companies, U-Neuron Biomedical ranks better than 75.78% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for U-Neuron Biomedical's Debt-to-Equity or its related term are showing as below:
ROCO:6973'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.04
Current: 0.04
During the past 6 years, the highest Debt-to-Equity Ratio of U-Neuron Biomedical was 0.04. The lowest was 0.00. And the median was 0.02.
ROCO:6973's Debt-to-Equity is ranked better than 75.78% of 962
companies
in the Biotechnology industry
Industry Median: 0.16
vs ROCO:6973: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
U-Neuron Biomedical Debt-to-Equity Related Terms
U-Neuron Biomedical Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for U-Neuron Biomedical's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6973 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, U-Neuron Biomedical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
U-Neuron Biomedical Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, U-Neuron Biomedical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where U-Neuron Biomedical's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
U-Neuron Biomedical (ROCO:6973) has a Debt-to-Equity of 0.04 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on U-Neuron Biomedical and its competitors. This is 100% above median its historical median of 0.02. According to the industry distribution chart, U-Neuron Biomedical ranks #233 out of 962 companies in the Biotechnology industry, placing it in the top 24.2%.
Is U-Neuron Biomedical's Debt-to-Equity too high?
U-Neuron Biomedical's current Debt-to-Equity of 0.04 is 100% above median its 10-year median of 0.02. The Biotechnology industry median Debt-to-Equity is 0.16. U-Neuron Biomedical's value of 0.04 is 75% below this industry median. Based on the distribution chart, U-Neuron Biomedical ranks #233 out of 962 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, U-Neuron Biomedical has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does U-Neuron Biomedical's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, U-Neuron Biomedical ranks #233 out of 962 companies for Debt-to-Equity. This places U-Neuron Biomedical in the top 24% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. U-Neuron Biomedical's value of 0.04 is 75% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.16, U-Neuron Biomedical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. U-Neuron Biomedical's current Debt-to-Equity of 0.04 is 75% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on U-Neuron Biomedical and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. U-Neuron Biomedical's current Debt-to-Equity is 0.04, which is 100% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is U-Neuron Biomedical stock overvalued right now?
Based on GuruFocus' analysis, U-Neuron Biomedical (ROCO:6973) is currently considered Possible Value Trap. The stock's GF Value™ is NT$70.46, compared to a current price of NT$45.35 — trading 35.6% below its estimated fair value. The current Debt-to-Equity is 0.04, which is 100% above median its 10-year median of 0.02 and 75% below the Biotechnology industry median of 0.16. U-Neuron Biomedical's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For U-Neuron Biomedical (ROCO:6973), the current Debt-to-Equity is 0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is U-Neuron Biomedical (ROCO:6973) Overvalued in 2026?
Based on GuruFocus' analysis, U-Neuron Biomedical stock appears to be undervalued.
The current stock price of NT$45.35 is trading 35.6% below its estimated GF Value™ of NT$70.46.
GuruFocus considers U-Neuron Biomedical to be Possible Value Trap.
Key valuation signals for ROCO:6973:
Debt-to-Equity: 0.04 (100% above median its 10-year median of 0.02)
GF Value™: NT$70.46 vs. price of NT$45.35 (35.6% below fair value)
Industry Position: 75% below the Biotechnology median (#233 of 962)
No single metric tells the full story. See the ROCO:6973 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.
36GF Score
Get the complete analysis for ROCO:6973
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6973 has been successfully added to your 
